A phase 2 study of the MDM2 inhibitor milademetan in patients with TP53-wild type and MDM2-amplified advanced or metastatic solid tumors (MANTRA-2)-MedSci.cn

A phase 2 study of the MDM2 inhibitor milademetan in patients with TP53-wild type and MDM2-amplified advanced or metastatic solid tumors (MANTRA-2)

Dumbrava, EE; Hanna, GJ; Cote, GM; Stinchcombe, T; Johnson, ML; Chen, C; Devarakonda, S; Shah, N; Xu, F; Doebele, RC; Gounder, MM

JOURNAL OF CLINICAL ONCOLOGY, 2022; 40 (16):

科室
- - 订阅+
  - 更多科室
工具
服务